michael barry
Senior Member
- Reaction score
- 14
Intercytex is supposedly finally going to start their phase 2 cloning trials sometime in September (dont hold your breath), but they have announced that they will only be testing 20 men over a ONE CENTIMETER SQUARE PATCH OF SCALP.
This is pathetic in my opinion. Aderans has not even entered phase one tests yet, and have made no announcements as to when they will be doing so. In my opinion that bunch is a LONG way away from releasing a protocol.
In more horrible news from Aderans, two of its lead researchers (and the one researcher with the largest reputation and the most impressive reputation, the "godfather of hair", Dr. Kurt Stenn) are working for a company called Follica now. I do not know whether or not they are both splitting time with Aderans or not but here is Follica's press release :
http://follicabio.com/
BACKGROUND: FOLLICLE BIOLOGY AND ITS ROLE IN SKIN
The follicle is an intricate tissue structure composed of numerous coordinated sub-structures (Figure 1). The cylindrically shaped hair follicle is composed of epithelial cells. The apocrine and sebaceous glands control sweat and sebum (lipid secretion) production respectively. Sebum plays a primary role in skin integrity, microbial defense, and the pathophysiology of acne.
The bulge structure housing the epithelial stem cell niche lies below the sebaceous gland. This population of cells controls the initial development of the follicle along with the different phases of the hair cycle. The “hair bulb†contains the dermal papilla and the pigment-generating melanocytes as well as other cells that modulate the hair growth cycle. The follicle is integrated into the surrounding skin through connections to the microvasculature and the sensory nervous system. The interplay among all of these sub-systems influences almost all aspects of skin biology, from inflammation and immune response to the neuroendocrine system.
FOLLICA'S TARGET INDICATIONS
Follica's primary focus is a novel, pre-publication approach to treating hair loss. As a secondary focus, Follica's platform technology will target the other high potential market opportunities related to the biology of the follicle, namely acne, pigmentation, and body odor.
Team
R. Rox Anderson, M.D., Co-Founder & Chair of the Scientific Advisory Board
Dr. Anderson has been a leading innovator in the medical laser field for over 20 years and several of his 41 issued patents have been developed into products currently used in the clinic. In his capacity as a Professor of Dermatology at Harvard Medical School , Dr. Anderson serves as the Director of the Massachusetts General Hospital Laser Center and the Director of the Wellman Laboratory of Photomedicine. Dr. Anderson is a Board Certified member of the American Board of Dermatology and world renowned thought leader that has published over 160 peer reviewed articles and has been a contributing editor to over 21 textbooks on the medical applications of lasers. Dr. Anderson also has experience advising numerous dermatology companies on how best to translate promising research into clinical products.
George Cotsarelis, M.D., Co-Founder & Scientific Advisory Board Member
A pioneer and foremost expert in epithelial stem cell biology, Dr. Cotsarelis' research led to the isolation and characterization of the expression pattern of stem cells from the bulge region of the follicle. Dr. Cotsarelis is an Associate Professor in the Department of Dermatology at the University of Pennsylvania and has an active clinical practice at the hospital affiliated with the university. He has published over 40 peer reviewed journal articles and has several issued and pending patents based on his scientific discoveries. Dr. Cotsarelis is also an active advisor to dermatology companies developing novel approaches to treating hair loss.
Vera Price, M.D., Co-Founder & Scientific Advisory Board Member
Dr. Vera Price is a Professor in the Department of Dermatology, University of California , San Francisco (UCSF) where she also directs the UCSF Hair Research Center , the Hair and Nail Clinic, and the UCSF Dermatology Faculty Practice. Dr. Price is Founding Chairman of the National Alopecia Areata Foundation and an active participant in other leading alopecia societies. Her research on quantitatively measuring hair growth in patients treated with Propecia (finasteride) and Rogaine (minoxidil), the hormonal regulation of the hair follicle, and immunopathologic and genetic studies in alopecia areata have yielded numerous significant contributions to the field.
Kurt Stenn, M.D., Co-Founder & Scientific Advisory Board Member
Dr. Stenn brings 30 years of expertise in hair follicle biology to the Follica team. After a 20 year distinguished academic career as a Professor of Pathology and Dermatology at the Yale University School of Medicine, Dr. Stenn spent 10 years as the Director of Skin Biology at Johnson & Johnson. During his career, he has lectured extensively on the biology of the hair follicle and has over 100 peer review scientific publications to his name. He is currently the Vice President of Research and Chief Scientific Officer of Aderans Research Institute, Inc., where he is pioneering novel approaches to hair transplantation.
Ron Cape PhD, Board Member
Daphne Zohar, Board Member
Stephen Prouty, PhD, Director of Research
David Steinberg, Interim COO
Kevin Pojasek PhD, VP of Strategy
As any of you can see Follica's focus is a "novel, pre-publication (meaning nothing in Scientific journals has been written about it) approach to hairloss. I can assure you this indication would be cellular in nature. They also want to use this art to treat conditions like acne, pigmentation, and body odor and "other conditions related to the hair follicle".
Dr. Stenn's credidentials are enormous in particular: Dr. Stenn brings 30 years of expertise in hair follicle biology to the Follica team. After a 20 year distinguished academic career as a Professor of Pathology and Dermatology at the Yale University School of Medicine, Dr. Stenn spent 10 years as the Director of Skin Biology at Johnson & Johnson. During his career, he has lectured extensively on the biology of the hair follicle and has over 100 peer review scientific publications to his name. He is currently the Vice President of Research and Chief Scientific Officer of Aderans Research Institute, Inc., where he is pioneering novel approaches to hair transplantation. He is also a senior advisor to one large company in the field of cosmetics............I forget which one but I think it was Johnson and Johnson.........so he knows his stuff.
Anyway, back to cloning....................things obviously aren't going that well. In fact I'd read an article by Costarialis and Stenn suggesting that cloning might have to be carried out outside the body in a 3 dimensional matrix and the full grown hair's be put back in the body. I really dont think they are having much luck in trials at Aderans in getting hair to consistently sprout on immuno-deficient mice with human skin grafted on their backs with human follicles.
The fact that human scalp skin is thinned out, aged, and fibriotic will no doubt mean that experiments will go even worse with human scalp skin for that protocol. I wish someone would have tried my ••••••• idea of implanting the stem cells in the fatty areas of the thighs and FUE'd them back out and put them on the head after they had fully formed follicles. I guess that idea just made too much damned horsesense.
Anyway, The Intercytex trials are supposedly going to be starting in the next few months, but one square centimeter of head hair proboably only will create 30 or so follicles if things go well. This does not inspire much confidence. ICX is a cash-strapped company and Dr. Paul Kemp, their president and the foremost tissue-engineering expert on earth (made the world's first organ from stem cells) spends much of his time trying to raise money speaking in conferences. If they do well in the phase two trial at ICX (big "if"), they will no doubt try a larger area.............maybe even a whole square inch. That would be another year............
ICX's prediction that they could perhaps offer cloning "in house" in Manchester England by 2008 looks like wishful thinking by this logic. I would not bet on cloning before 2010, and even that is a bit optomistic. The researchers themselves, whove hairsite.com poster James Bond has spoken with in an interview, dont even "name a date" themselves. They simply have to wait and see how various injection and culturing protocols do in these tiny tests with regards to efficacy, direction, consistency. Safety has been established however, and thats good news.
We also have to worry about the hairs only growing for one cycle and not regenerating. Sort of like genetically modified crop's seeds not being able to produce new produce on their own (they can't), perhaps these induced hairs wont regenerate after the first rest phase after three years or so. Thats also a concern.
2011-2012. My opinion. Hope I'm wrong, and a breakthrough here or there could speed that up
This is pathetic in my opinion. Aderans has not even entered phase one tests yet, and have made no announcements as to when they will be doing so. In my opinion that bunch is a LONG way away from releasing a protocol.
In more horrible news from Aderans, two of its lead researchers (and the one researcher with the largest reputation and the most impressive reputation, the "godfather of hair", Dr. Kurt Stenn) are working for a company called Follica now. I do not know whether or not they are both splitting time with Aderans or not but here is Follica's press release :
http://follicabio.com/
BACKGROUND: FOLLICLE BIOLOGY AND ITS ROLE IN SKIN
The follicle is an intricate tissue structure composed of numerous coordinated sub-structures (Figure 1). The cylindrically shaped hair follicle is composed of epithelial cells. The apocrine and sebaceous glands control sweat and sebum (lipid secretion) production respectively. Sebum plays a primary role in skin integrity, microbial defense, and the pathophysiology of acne.
The bulge structure housing the epithelial stem cell niche lies below the sebaceous gland. This population of cells controls the initial development of the follicle along with the different phases of the hair cycle. The “hair bulb†contains the dermal papilla and the pigment-generating melanocytes as well as other cells that modulate the hair growth cycle. The follicle is integrated into the surrounding skin through connections to the microvasculature and the sensory nervous system. The interplay among all of these sub-systems influences almost all aspects of skin biology, from inflammation and immune response to the neuroendocrine system.
FOLLICA'S TARGET INDICATIONS
Follica's primary focus is a novel, pre-publication approach to treating hair loss. As a secondary focus, Follica's platform technology will target the other high potential market opportunities related to the biology of the follicle, namely acne, pigmentation, and body odor.
Team
R. Rox Anderson, M.D., Co-Founder & Chair of the Scientific Advisory Board
Dr. Anderson has been a leading innovator in the medical laser field for over 20 years and several of his 41 issued patents have been developed into products currently used in the clinic. In his capacity as a Professor of Dermatology at Harvard Medical School , Dr. Anderson serves as the Director of the Massachusetts General Hospital Laser Center and the Director of the Wellman Laboratory of Photomedicine. Dr. Anderson is a Board Certified member of the American Board of Dermatology and world renowned thought leader that has published over 160 peer reviewed articles and has been a contributing editor to over 21 textbooks on the medical applications of lasers. Dr. Anderson also has experience advising numerous dermatology companies on how best to translate promising research into clinical products.
George Cotsarelis, M.D., Co-Founder & Scientific Advisory Board Member
A pioneer and foremost expert in epithelial stem cell biology, Dr. Cotsarelis' research led to the isolation and characterization of the expression pattern of stem cells from the bulge region of the follicle. Dr. Cotsarelis is an Associate Professor in the Department of Dermatology at the University of Pennsylvania and has an active clinical practice at the hospital affiliated with the university. He has published over 40 peer reviewed journal articles and has several issued and pending patents based on his scientific discoveries. Dr. Cotsarelis is also an active advisor to dermatology companies developing novel approaches to treating hair loss.
Vera Price, M.D., Co-Founder & Scientific Advisory Board Member
Dr. Vera Price is a Professor in the Department of Dermatology, University of California , San Francisco (UCSF) where she also directs the UCSF Hair Research Center , the Hair and Nail Clinic, and the UCSF Dermatology Faculty Practice. Dr. Price is Founding Chairman of the National Alopecia Areata Foundation and an active participant in other leading alopecia societies. Her research on quantitatively measuring hair growth in patients treated with Propecia (finasteride) and Rogaine (minoxidil), the hormonal regulation of the hair follicle, and immunopathologic and genetic studies in alopecia areata have yielded numerous significant contributions to the field.
Kurt Stenn, M.D., Co-Founder & Scientific Advisory Board Member
Dr. Stenn brings 30 years of expertise in hair follicle biology to the Follica team. After a 20 year distinguished academic career as a Professor of Pathology and Dermatology at the Yale University School of Medicine, Dr. Stenn spent 10 years as the Director of Skin Biology at Johnson & Johnson. During his career, he has lectured extensively on the biology of the hair follicle and has over 100 peer review scientific publications to his name. He is currently the Vice President of Research and Chief Scientific Officer of Aderans Research Institute, Inc., where he is pioneering novel approaches to hair transplantation.
Ron Cape PhD, Board Member
Daphne Zohar, Board Member
Stephen Prouty, PhD, Director of Research
David Steinberg, Interim COO
Kevin Pojasek PhD, VP of Strategy
As any of you can see Follica's focus is a "novel, pre-publication (meaning nothing in Scientific journals has been written about it) approach to hairloss. I can assure you this indication would be cellular in nature. They also want to use this art to treat conditions like acne, pigmentation, and body odor and "other conditions related to the hair follicle".
Dr. Stenn's credidentials are enormous in particular: Dr. Stenn brings 30 years of expertise in hair follicle biology to the Follica team. After a 20 year distinguished academic career as a Professor of Pathology and Dermatology at the Yale University School of Medicine, Dr. Stenn spent 10 years as the Director of Skin Biology at Johnson & Johnson. During his career, he has lectured extensively on the biology of the hair follicle and has over 100 peer review scientific publications to his name. He is currently the Vice President of Research and Chief Scientific Officer of Aderans Research Institute, Inc., where he is pioneering novel approaches to hair transplantation. He is also a senior advisor to one large company in the field of cosmetics............I forget which one but I think it was Johnson and Johnson.........so he knows his stuff.
Anyway, back to cloning....................things obviously aren't going that well. In fact I'd read an article by Costarialis and Stenn suggesting that cloning might have to be carried out outside the body in a 3 dimensional matrix and the full grown hair's be put back in the body. I really dont think they are having much luck in trials at Aderans in getting hair to consistently sprout on immuno-deficient mice with human skin grafted on their backs with human follicles.
The fact that human scalp skin is thinned out, aged, and fibriotic will no doubt mean that experiments will go even worse with human scalp skin for that protocol. I wish someone would have tried my ••••••• idea of implanting the stem cells in the fatty areas of the thighs and FUE'd them back out and put them on the head after they had fully formed follicles. I guess that idea just made too much damned horsesense.
Anyway, The Intercytex trials are supposedly going to be starting in the next few months, but one square centimeter of head hair proboably only will create 30 or so follicles if things go well. This does not inspire much confidence. ICX is a cash-strapped company and Dr. Paul Kemp, their president and the foremost tissue-engineering expert on earth (made the world's first organ from stem cells) spends much of his time trying to raise money speaking in conferences. If they do well in the phase two trial at ICX (big "if"), they will no doubt try a larger area.............maybe even a whole square inch. That would be another year............
ICX's prediction that they could perhaps offer cloning "in house" in Manchester England by 2008 looks like wishful thinking by this logic. I would not bet on cloning before 2010, and even that is a bit optomistic. The researchers themselves, whove hairsite.com poster James Bond has spoken with in an interview, dont even "name a date" themselves. They simply have to wait and see how various injection and culturing protocols do in these tiny tests with regards to efficacy, direction, consistency. Safety has been established however, and thats good news.
We also have to worry about the hairs only growing for one cycle and not regenerating. Sort of like genetically modified crop's seeds not being able to produce new produce on their own (they can't), perhaps these induced hairs wont regenerate after the first rest phase after three years or so. Thats also a concern.
2011-2012. My opinion. Hope I'm wrong, and a breakthrough here or there could speed that up